Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Pharmacokinetics of HQP1351 in Resistant CML
NCT03882281Phase 1Completed
- Sponsor
- Ascentage Pharma
- Start
- Mar 2019
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olverembatinib in chronic myeloid leukemia (CML) (2 arms), sponsored by Ascentage Pharma. Primary endpoints: Area under the curve from the time of dosing to infinity, Area under the curve from the time of dosing to the last measurable concentration and 6 more. Started Mar 2019; status: completed.
02
Drugs
olverembatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03882281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03882281.